Weifeng Mi

NHC Key Laboratory Of Mental Health, NHC Key Laboratory Of Mental Health
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Fecal microbiota transplantation-based treatment protocol for chronic insomnia disorder: A randomized, double-blind, placebo-controlled trial.

Fecal microbiota transplantation-based treatment protocol for chronic insomnia disorder: A randomized, double-blind, placebo-controlled trial.

Journal: Journal of internal medicine

Published: July 22, 2026

NeuMTL: A Unified Multimodal Framework for Multi-Task Prediction in CNS Drug Discovery.

NeuMTL: A Unified Multimodal Framework for Multi-Task Prediction in CNS Drug Discovery.

Journal: Journal of chemical information and modeling

Published: January 02, 2026

Causal role of immune cells in major depressive disorder and bipolar disorder: Mendelian randomization (MR) study.

Causal role of immune cells in major depressive disorder and bipolar disorder: Mendelian randomization (MR) study.

Journal: Journal of affective disorders

Published: April 06, 2024

Morinda officinalis oligosaccharides modulate the default-mode network homogeneity in major depressive disorder at rest.

Morinda officinalis oligosaccharides modulate the default-mode network homogeneity in major depressive disorder at rest.

Journal: Psychiatry research. Neuroimaging

Published: July 26, 2023

A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder.

A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder.

Journal: Translational psychiatry

Published: October 18, 2022

Reliability and validity of the Chinese version of the Oxford Depression Questionnaire (ODQ-Chinese).

Reliability and validity of the Chinese version of the Oxford Depression Questionnaire (ODQ-Chinese).

Journal: Journal of affective disorders

Published: December 31, 2021

Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial.

Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial.

Journal: The international journal of neuropsychopharmacology

Published: August 11, 2021

Prevalence and risk factors of agitation in newly hospitalized schizophrenia patients in China: An observational survey.

Prevalence and risk factors of agitation in newly hospitalized schizophrenia patients in China: An observational survey.

Journal: Psychiatry research

Published: August 18, 2016

Association of ABCB1 Gene Polymorphisms with Efficacy and Adverse Reaction to Risperidone or Paliperidone in Han Chinese Schizophrenic Patients.

Association of ABCB1 Gene Polymorphisms with Efficacy and Adverse Reaction to Risperidone or Paliperidone in Han Chinese Schizophrenic Patients.

Journal: Neuroscience bulletin

Published: March 25, 2016

Genome-Wide Association Study Suggested the PTPRD Polymorphisms Were Associated With Weight Gain Effects of Atypical Antipsychotic Medications.

Genome-Wide Association Study Suggested the PTPRD Polymorphisms Were Associated With Weight Gain Effects of Atypical Antipsychotic Medications.

Journal: Schizophrenia bulletin

Published: December 15, 2015

A pharmacogenomic study revealed an association between SLC6A4 and risperidone-induced weight gain in Chinese Han population.

A pharmacogenomic study revealed an association between SLC6A4 and risperidone-induced weight gain in Chinese Han population.

Journal: Pharmacogenomics

Published: November 12, 2015

High relapse rate and poor medication adherence in the Chinese population with schizophrenia: results from an observational survey in the People's Republic of China.

High relapse rate and poor medication adherence in the Chinese population with schizophrenia: results from an observational survey in the People's Republic of China.

Journal: Neuropsychiatric disease and treatment

Published: June 10, 2015

Showing 1-12 of 16

Last Updated: 09/26/2026